Physician profile
Mark Vaisman
NPI 1891976189
$1,651.29
in general payments reported to CMS, 2019-2025
15 companies · $472 in 2025
The $472 reported for 2025 was more than what 83% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $19.09 · 2021: $225 · 2022: $375 · 2023: $197 · 2024: $123 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $446.89 | 2022-2025 | Krystexxa, Repatha |
| Abbvie INC. | $248.26 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.12 | 2023-2024 | Xifaxan |
| Novo Nordisk INC | $168.95 | 2021 | |
| Janssen Pharmaceuticals, INC | $124.99 | 2022 | |
| Glaxosmithkline, LLC. | $121.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.27 | 2025 | Ofev |
| Merck Sharp & Dohme LLC | $57.94 | 2019-2021 | |
| Mannkind Corporation | $29.60 | 2019 | |
| Shire North American Group INC | $24.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.33 | 2021 | |
| Biofire Diagnostics, LLC | $17.94 | 2019 | |
| Gilead Sciences, INC. | $15.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.33 | 2021 | |
| Circassia INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vaisman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.